Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Azithromycin × Other hematologic neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1 Gastrointestinal 1 Dermatologic 1

Conditions

Hematologic Neoplasms 1 COVID-19 1

Interventions

Cytarabine 807 Cyclophosphamide 795 fludarabine 457 venetoclax 432 fludarabine phosphate 419 Azacitidine 411 Rituximab 389 Methotrexate 358 Etoposide 291 Filgrastim 262 Busulfan 251 Vincristine 248 Daunorubicin 248 Dexamethasone 245 Peripheral Blood Stem Cell Transplantation 220 Whole-Body Irradiation 213 Decitabine 208 Mycophenolic Acid 202 Imatinib Mesylate 192 Granulocyte Colony-Stimulating Factor 185 Idarubicin 183 Tacrolimus 180 Melphalan 180 Cyclosporine 162 Doxorubicin 158 Radiotherapy 154 Mitoxantrone 148 Dasatinib 145 Prednisone 142 Lenalidomide 140

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04392128 2020-09-04

HYACINTHE

Institut de cancérologie Strasbourg Europe

Phase 2 Withdrawn

Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡